Product Images Eliquis

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Eliquis NDC 71610-811 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label - 71610 811 83

Label - 71610 811 83

Aphena - Aphena

Aphena - Aphena

Apixaban Chemical Structure - apixaban struct

Apixaban Chemical Structure - apixaban struct

ARISTOTLE Forest Plot - eliquis clin forest fig5

ARISTOTLE Forest Plot - eliquis clin forest fig5

ARISTOTLE Major Bleeding Forest Plot - eliquis forest fig1

ARISTOTLE Major Bleeding Forest Plot - eliquis forest fig1

ARISTOTLE Kaplan-Meier Curve - eliquis km fig4

ARISTOTLE Kaplan-Meier Curve - eliquis km fig4

Effect of Coadministered Drugs on Pharmacokinetics of Apixaban - eliquis pkplot drugs fig2

Effect of Coadministered Drugs on Pharmacokinetics of Apixaban - eliquis pkplot drugs fig2

This text provides information on the drug-drug interactions and the effect on pharmacokinetics with specific drugs acting as inhibitors or inducers of P-gp and CYP3A4 enzymes. It includes data on the fold change in PK (pharmacokinetics) and the corresponding 90% confidence intervals for drugs like Ketoconazole, Clarithromycin, Diltiazem, Naproxen, and Rifampin. The relative changes in AUC values are also noted for each drug interaction.*

O:\E-Submissions\PBO\PRODUCTS\Eliquis 202155\08. PAS ESRD Dosing\01. Orig Submission\Source\eliquis-pkplot-pop-fig3.jpg - eliquis pkplot pop fig3

O:\E-Submissions\PBO\PRODUCTS\Eliquis 202155\08. PAS ESRD Dosing\01. Orig Submission\Source\eliquis-pkplot-pop-fig3.jpg - eliquis pkplot pop fig3

This text provides information on population descriptions, PK fold change, and recommendations for dose adjustments based on different parameters such as age, body weight, renal impairment, and hepatic impairment. It outlines specific scenarios where dose adjustments may or may not be necessary for optimal treatment outcomes.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.